Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Crispr Therapeutics is a biotechnology business based in the US. Crispr Therapeutics stocks (CRSP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $62.78 – a decrease of 3.71% over the previous week. Crispr Therapeutics employs 458 staff and has a trailing 12-month revenue of around $100.3 million.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Latest market close | $62.59 |
|---|---|
| 52-week range | $38.94 - $86.95 |
| 50-day moving average | $53.34 |
| 200-day moving average | $54.67 |
| Wall St. target price | $83.42 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-6.79 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $62.59 from 2023-06-08
| 1 week (2023-06-02) | -3.71% |
|---|---|
| 1 month (2023-05-09) | -1.31% |
| 3 months (2023-03-09) | 36.69% |
| 6 months (2022-12-09) | 27.76% |
| 1 year (2022-06-08) | -15.22% |
|---|---|
| 2 years (2021-06-09) | -47.83% |
| 3 years (2020-06-09) | 63.26 |
| 5 years (2018-06-08) | 68.15 |
| Revenue TTM | $100.3 million |
|---|---|
| Gross profit TTM | $-570,697,000 |
| Return on assets TTM | -14.48% |
| Return on equity TTM | -25.56% |
| Profit margin | 0% |
| Book value | $23.52 |
| Market capitalisation | $5.1 billion |
TTM: trailing 12 months
We're not expecting Crispr Therapeutics to pay a dividend over the next 12 months.
Crispr Therapeutics's shares were split on a 333333:100 basis on 18 July 2016. So if you had owned 100 shares the day before before the split, the next day you'd have owned 333333 shares. This wouldn't directly have changed the overall worth of your Crispr Therapeutics shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Crispr Therapeutics shares which in turn could have impacted Crispr Therapeutics's share price.
Over the last 12 months, Crispr Therapeutics's shares have ranged in value from as little as $38.94 up to $86.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Crispr Therapeutics's is 1.7016. This would suggest that Crispr Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…From personal and payday loans to lines of credit, compare loans for bad credit in Edmonton.
This guide provides step-by-step instructions on how to buy Sui, lists some exchanges where you can get it and provides daily price data on (SUI).
This guide provides step-by-step instructions on how to buy Pepe, lists some exchanges where you can get it and provides daily price data on (PEPE).
This guide provides step-by-step instructions on how to buy Arbitrum, lists some exchanges where you can get it and provides daily price data on (ARB).
This guide provides step-by-step instructions on how to buy SSV Network, lists some exchanges where you can get it and provides daily price data on (SSV).
This guide provides step-by-step instructions on how to buy USDD, lists some exchanges where you can get it and provides daily price data on (USDD).
This guide provides step-by-step instructions on how to buy Blur, lists some exchanges where you can get it and provides daily price data on (BLUR).
This guide provides step-by-step instructions on how to buy FLOKI Inu, lists some exchanges where you can get it and provides daily price data on (FLOKI).
This guide provides step-by-step instructions on how to buy Aptos, lists some exchanges where you can get it and provides daily price data on (APT).
This guide provides step-by-step instructions on how to buy EthereumPoW, lists some exchanges where you can get it and provides daily price data on (ETHW).
